Published in Amyotroph Lateral Scler on September 14, 2010
How can we improve clinical trials in amyotrophic lateral sclerosis? Nat Rev Neurol (2011) 0.89
A Pilot Trial of Pioglitazone HCl and Tretinoin in ALS: Cerebrospinal Fluid Biomarkers to Monitor Drug Efficacy and Predict Rate of Disease Progression. Neurol Res Int (2012) 0.82
ALS biomarkers for therapy development: State of the field and future directions. Muscle Nerve (2015) 0.81
Neuroprotection for amyotrophic lateral sclerosis: role of stem cells, growth factors, and gene therapy. Cent Nerv Syst Agents Med Chem (2012) 0.81
Gacyclidine improves the survival and reduces motor deficits in a mouse model of amyotrophic lateral sclerosis. Front Cell Neurosci (2013) 0.80
Use of biomarkers in ALS drug development and clinical trials. Brain Res (2014) 0.79
Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis. Neurotherapeutics (2016) 0.78
Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells. Pigment Cell Melanoma Res (2014) 0.77
Potential new complication in drug therapy development for amyotrophic lateral sclerosis. Expert Rev Neurother (2016) 0.75
Whole-genome analysis of sporadic amyotrophic lateral sclerosis. N Engl J Med (2007) 3.33
Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS One (2010) 2.49
A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph Lateral Scler (2008) 2.28
Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (2007) 2.25
Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem (2005) 1.91
Transgenic rat model of neurodegeneration caused by mutation in the TDP gene. PLoS Genet (2010) 1.81
Reactive astrocytes secrete lcn2 to promote neuron death. Proc Natl Acad Sci U S A (2013) 1.59
Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control (2010) 1.52
Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle Nerve (2010) 1.48
Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure (2007) 1.31
Alterations in G(1) to S phase cell-cycle regulators during amyotrophic lateral sclerosis. Am J Pathol (2003) 1.27
Functional repression of cAMP response element in 6-hydroxydopamine-treated neuronal cells. J Biol Chem (2006) 1.25
Ectopic localization of phosphorylated histone H3 in Alzheimer's disease: a mitotic catastrophe? Acta Neuropathol (2003) 1.24
YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor. Am J Pathol (2008) 1.23
Mechanisms, models and biomarkers in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener (2013) 1.16
Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem (2011) 1.10
Cystatin C: a candidate biomarker for amyotrophic lateral sclerosis. PLoS One (2010) 1.08
Elevated expression of a regulator of the G2/M phase of the cell cycle, neuronal CIP-1-associated regulator of cyclin B, in Alzheimer's disease. J Neurosci Res (2004) 1.03
Environmental and occupational risk factors for amyotrophic lateral sclerosis: a case-control study. Neurodegener Dis (2013) 1.03
Altered distribution of cell cycle transcriptional regulators during Alzheimer disease. J Neuropathol Exp Neurol (2002) 1.02
SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. JAMA Neurol (2013) 1.01
Altered subcellular distribution of c-Abl in Alzheimer's disease. J Alzheimers Dis (2009) 0.99
Focal adhesions regulate Abeta signaling and cell death in Alzheimer's disease. Biochim Biophys Acta (2006) 0.98
Fetal Alz-50 clone 1 interacts with the human orthologue of the Kelch-like Ech-associated protein. Biochemistry (2004) 0.96
Hyperphosphorylation of the retinoblastoma gene product and altered subcellular distribution of E2F-1 during Alzheimer's disease and amyotrophic lateral sclerosis. J Alzheimers Dis (2001) 0.96
Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42. Biomark Med (2012) 0.95
The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients. Acta Neuropathol (2012) 0.95
Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph Lateral Scler (2012) 0.95
Alzheimer disease pathology in amyotrophic lateral sclerosis. Acta Neuropathol (2004) 0.94
Biochemical alterations associated with ALS. Amyotroph Lateral Scler (2011) 0.94
The application of biomarkers in clinical trials for motor neuron disease. Biomark Med (2010) 0.92
Pesticide exposure as a risk factor for amyotrophic lateral sclerosis: a meta-analysis of epidemiological studies: pesticide exposure as a risk factor for ALS. Environ Res (2012) 0.91
pNfH is a promising biomarker for ALS. Amyotroph Lateral Scler Frontotemporal Degener (2012) 0.91
Protein biomarkers for amyotrophic lateral sclerosis. Expert Rev Proteomics (2008) 0.91
Therapeutic neuroprotective agents for amyotrophic lateral sclerosis. Cell Mol Life Sci (2013) 0.88
Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers. Int J Gynecol Cancer (2011) 0.88
Increased expression of p130 in Alzheimer disease. Neurochem Res (2006) 0.87
Retinoblastoma protein phosphorylation at multiple sites is associated with neurofibrillary pathology in Alzheimer disease. Int J Clin Exp Pathol (2008) 0.87
Survival outcomes in endometrial cancer patients are associated with CXCL12 and estrogen receptor expression. Int J Cancer (2012) 0.84
Novel Death Defying Domain in Met entraps the active site of caspase-3 and blocks apoptosis in hepatocytes. Hepatology (2014) 0.82
A Pilot Trial of Pioglitazone HCl and Tretinoin in ALS: Cerebrospinal Fluid Biomarkers to Monitor Drug Efficacy and Predict Rate of Disease Progression. Neurol Res Int (2012) 0.82
Measurement of cystatin C functional activity in the cerebrospinal fluid of amyotrophic lateral sclerosis and control subjects. Fluids Barriers CNS (2013) 0.82
Paxillin and hydrogen peroxide-inducible clone 5 expression and distribution in control and Alzheimer disease hippocampi. J Neuropathol Exp Neurol (2010) 0.81
Neuroprotection for amyotrophic lateral sclerosis: role of stem cells, growth factors, and gene therapy. Cent Nerv Syst Agents Med Chem (2012) 0.81
DNA damage induces cdk2 protein levels and histone H2B phosphorylation in SH-SY5Y neuroblastoma cells. J Alzheimers Dis (2005) 0.81
Assessment of Protein Stability in Cerebrospinal Fluid Using Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Protein Profiling. Clin Proteomics (2006) 0.80
Retinoid signaling alterations in amyotrophic lateral sclerosis. Am J Neurodegener Dis (2012) 0.80
Von Willebrand factor promoter targets the expression of amyloid beta protein precursor to brain vascular endothelial cells of transgenic mice. J Alzheimers Dis (2003) 0.80
p53 and Cell Cycle Proteins Participate in Spinal Motor Neuron Cell Death in ALS. Open Pathol J (2010) 0.80
Proposed BioRepository platform solution for the ALS research community. Amyotroph Lateral Scler (2010) 0.80
Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease. Mol Diagn Ther (2006) 0.79
Usefulness of skin biopsies in the evaluation and management of patients with suspected small fiber neuropathy. Int J Neurosci (2012) 0.79
Altered expression and distribution of FAC1 during NGF-induced neurite outgrowth of PC12 cells. Neuroreport (2003) 0.78
Comparative proteomic profiling of cerebrospinal fluid between living and post mortem ALS and control subjects. Amyotroph Lateral Scler (2007) 0.78
Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. Amyotroph Lateral Scler Frontotemporal Degener (2014) 0.78
Chemokines and Cancer Progression: A Qualitative Review on the Role of Stromal Cell-derived Factor 1-alpha and CXCR4 in Endometrial Cancer. Cancer Microenviron (2010) 0.78
Identification of a complex between fibronectin and aggrecan G3 domain in synovial fluid of patients with painful meniscal pathology. Clin Biochem (2010) 0.77
Retrospective chart review of duloxetine and pregabalin in the treatment of painful neuropathy. Int J Neurosci (2011) 0.77
ALS Untangled No. 20: the Deanna protocol. Amyotroph Lateral Scler Frontotemporal Degener (2013) 0.77
Carbonic anhydrase I is recognized by an SOD1 antibody upon biotinylation of human spinal cord extracts. Int J Mol Sci (2010) 0.77
Increased Cyclin G1 Immunoreactivity During Alzheimer's Disease. J Alzheimers Dis (1999) 0.76
Post-lumbar puncture headache is reduced with use of atraumatic needles in ALS. Amyotroph Lateral Scler Frontotemporal Degener (2013) 0.76
Genetic variation in ESR2 and estrogen receptor-beta expression in lung tumors. Cancer Epidemiol (2013) 0.75
The 12th International Symposium on ALS/MND: scientific advancements in amyotrophic lateral sclerosis. November 18-20, 2001, Oakland, Calif. Brain Pathol (2002) 0.75
PhD graduate training programs in pathology: 2003 report from the American Society for Investigative Pathology workshop on pathology graduate education. Hum Pathol (2004) 0.75
Electrophysiological alterations during hypnosis for ego-enhancement: a preliminary investigation. Am J Clin Hypn (2004) 0.75
Neuromuscular Highlights-AAN 2005. J Clin Neuromuscul Dis (2006) 0.75